Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals

Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen

Fineline Cube Nov 17, 2023

Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...

Company Deals

Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry

Fineline Cube Nov 16, 2023

Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum...

Company Drug

SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA

Fineline Cube Nov 16, 2023

SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...

Company

Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Nov 16, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published...

Company Medical Device

Sino Medical Sciences Technology’s HT Supreme Stent Gains Brazilian Market Approval

Fineline Cube Nov 16, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced...

Company Deals

Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies

Fineline Cube Nov 16, 2023

Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...

Company Deals

AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management

Fineline Cube Nov 16, 2023

US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...

Company Drug

Fujian Cosunter’s COVID-19 Therapy GST-HG171/Ritonavir NDA Accepted by NMPA

Fineline Cube Nov 16, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that its...

Company Deals

Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment

Fineline Cube Nov 16, 2023

Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US...

Company Deals

Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal

Fineline Cube Nov 16, 2023

Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal...

Company Drug

China’s NMPA Accepts EOC Pharma Group’s Filing for Vascepa (Icosapent Ethyl) for Review

Fineline Cube Nov 15, 2023

The China-based EOC Pharma Group has achieved a significant milestone with the National Medical Products...

Company Deals

Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition

Fineline Cube Nov 15, 2023

The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...

Company

Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches

Fineline Cube Nov 15, 2023

Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this...

Company Deals

Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research

Fineline Cube Nov 15, 2023

Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with...

Company Drug

EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation

Fineline Cube Nov 15, 2023

The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...

Company Deals

PRECEDO Secures Over RMB 100 Million in Financing to Build Living Primary Cancer Cell Bank

Fineline Cube Nov 15, 2023

PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB...

Company Deals

Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes

Fineline Cube Nov 15, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to...

Policy / Regulatory

China’s National Allied Procurement Office Announces VBP Tender for Medical Consumables and 3D Printing Products

Fineline Cube Nov 15, 2023

The National Allied Procurement Office has released a notification outlining plans for a volume-based procurement...

Company Medical Device

Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU

Fineline Cube Nov 15, 2023

China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received...

Company Deals

Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin

Fineline Cube Nov 15, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership...

Posts pagination

1 … 380 381 382 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.